{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:23:55Z","timestamp":1783092235882,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04485-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:14:46Z","timestamp":1783091686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant metformin on clinical and pathological response in non-diabetic patients with non-metastatic breast cancer: an updated systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-6384","authenticated-orcid":false,"given":"Diego","family":"Arriaga\u2010Izabal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7939-2186","authenticated-orcid":false,"given":"Francisco","family":"Morales\u2010Lazcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-0766","authenticated-orcid":false,"given":"Uriel A.","family":"Angulo-Zamudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-0639","authenticated-orcid":false,"given":"Adrian","family":"Canizalez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-3383","authenticated-orcid":false,"given":"Nidia","family":"Le\u00f3n-Sicairos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4485_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103851","volume":"79","author":"L Liao","year":"2025","unstructured":"Liao L. Inequality in breast cancer: global statistics from 2022 to 2050. Breast. 2025;79:103851. https:\/\/doi.org\/10.1016\/j.breast.2024.103851.","journal-title":"Breast"},{"issue":"1","key":"4485_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.hoc.2025.07.011","volume":"40","author":"G Montagna","year":"2026","unstructured":"Montagna G, Ferraro E, Pilewskie ML. Neoadjuvant chemotherapy for nonmetastatic breast cancer: how response impacts locoregional and adjuvant systemic therapy decision making. Hematol Oncol Clin North Am. 2026;40(1):133\u201353. https:\/\/doi.org\/10.1016\/j.hoc.2025.07.011.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"4485_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.surge.2023.04.001","volume":"21","author":"A Ofri","year":"2023","unstructured":"Ofri A, Elstner K, Mann G, Kumar S, Warrier S. Neoadjuvant chemotherapy in non-metastatic breast cancer: the surgeon\u2019s perspective. Surgeon. 2023;21(6):356\u201360. https:\/\/doi.org\/10.1016\/j.surge.2023.04.001.","journal-title":"Surgeon"},{"key":"4485_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104122","author":"K Sugiyama","year":"2025","unstructured":"Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I. Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors? ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104122.","journal-title":"ESMO Open"},{"issue":"2","key":"4485_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","volume":"11","author":"NF Aykan","year":"2020","unstructured":"Aykan NF, \u00d6zatl\u0131 T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53\u201373. https:\/\/doi.org\/10.5306\/wjco.v11.i2.53.","journal-title":"World J Clin Oncol"},{"issue":"10","key":"4485_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e43069","volume":"11","author":"M Antonini","year":"2025","unstructured":"Antonini M, Mattar A, Pereira TM, Lemos-Oliveira L, Di\u00f3genes-Teixera M, Gon\u00e7alves-Amorim A, et al. Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: a systematic review and meta-analysis of real-world data. Heliyon. 2025;11(10):e43069. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e43069.","journal-title":"Heliyon"},{"key":"4485_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114676","volume":"162","author":"SS Bashraheel","year":"2023","unstructured":"Bashraheel SS, Kheraldine H, Khalaf S, Moustafa AEA. Metformin and HER2-positive breast cancer: mechanisms and therapeutic implications. Biomed Pharmacother. 2023;162:114676. https:\/\/doi.org\/10.1016\/j.biopha.2023.114676.","journal-title":"Biomed Pharmacother"},{"key":"4485_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118507","volume":"191","author":"H Lv","year":"2025","unstructured":"Lv H, Gong H, Zhao R, Gao X, Liu W., Zhao L, et al. From basics to clinics: New opportunities for metformin in tumor metabolic intervention and treatment. Biomed Pharmacother. 2025;191:118507. https:\/\/doi.org\/10.1016\/j.biopha.2025.118507.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4485_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3390\/cancers12092482","volume":"12","author":"SM Samuel","year":"2020","unstructured":"Samuel SM, Varghese E, Koklesov\u00e1 L, L\u00ed\u0161kov\u00e1 A, Kubatka P, B\u00fcsselberg D. Counteracting Chemoresistance with Metformin in breast cancers: targeting cancer stem cells. Cancers (Basel). 2020;12(9):2482. https:\/\/doi.org\/10.3390\/cancers12092482.","journal-title":"Cancers (Basel)"},{"key":"4485_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/0471141755.ph1425s61","author":"B Bao","year":"2013","unstructured":"Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013. https:\/\/doi.org\/10.1002\/0471141755.ph1425s61.","journal-title":"Curr Protoc Pharmacol"},{"key":"4485_CR11","doi-asserted-by":"publisher","first-page":"9653244","DOI":"10.1155\/2022\/9653244","volume":"2022","author":"S Bisht","year":"2022","unstructured":"Bisht S, Nigam M, Kunjwal SS, Sergey P, Mishra AP, Sharifi-Rad J. Cancer stem cells: from an insight into the basics to recent advances and therapeutic targeting. Stem Cells Int. 2022;2022:9653244. https:\/\/doi.org\/10.1155\/2022\/9653244.","journal-title":"Stem Cells Int"},{"issue":"20","key":"4485_CR12","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","volume":"27","author":"S Jiralerspong","year":"2009","unstructured":"Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297\u2013302. https:\/\/doi.org\/10.1200\/JCO.2009.19.6410.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4485_CR13","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1111\/bcp.16193","volume":"90","author":"MA Serageldin","year":"2024","unstructured":"Serageldin MA, El-Bassiouny NA, El-Kerm Y, Aly RG, Helmy MW, El-Mas M et al. A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: the METNEO study. Br J Clin Pharmacol. 2024;90(12):3160\u201375. https:\/\/doi.org\/10.1111\/bcp.16193.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4485_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-022-06821-y","volume":"197","author":"J Huang","year":"2023","unstructured":"Huang J, Tong Y, Hong J, Wu J, He J, Chen W, et al. Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized phase II NeoMET trial. Breast Cancer Res Treat. 2023;197(3):525\u201333. https:\/\/doi.org\/10.1007\/s10549-022-06821-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4485_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2298\/AOO180312003L","volume":"24","author":"R Liubota","year":"2018","unstructured":"Liubota R, Cheshuk V, Zotov O, Vereshchako R, Anikusko M, Liubota I, et al. Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome. Arch Oncol. 2018;24(1):1\u20135. https:\/\/doi.org\/10.2298\/AOO180312003L.","journal-title":"Arch Oncol"},{"key":"4485_CR16","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1038\/s41598-022-11138-3","volume":"12","author":"HE Barakat","year":"2022","unstructured":"Barakat HE, Hussein RRS, Elberry AA, Zaki MA, Ramadan ME. The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Sci Rep. 2022;12:7656. https:\/\/doi.org\/10.1038\/s41598-022-11138-3.","journal-title":"Sci Rep"},{"key":"4485_CR17","doi-asserted-by":"publisher","DOI":"10.21608\/ejhm.2020.120446","author":"ASA Said","year":"2020","unstructured":"Said ASA. Role of metformin in combination with trastuzumab and neoadjuvant chemotherapy in treatment of HER-2 positive breast cancer. Egypt J Hosp Med. 2020. https:\/\/doi.org\/10.21608\/ejhm.2020.120446.","journal-title":"Egypt J Hosp Med"},{"issue":"15_suppl","key":"4485_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2016.34.15_suppl.579","volume":"34","author":"C Arce-Salinas","year":"2016","unstructured":"Arce-Salinas C, Alamilla G, Flores-Diaz D, Zuratzi-Deneken C, Mendoza-Galindo L, Ram\u00edrez-Morales R, et al. Randomized, double blind trial to evaluate the safety and efficacy of metformin vs placebo plus neoadjuvant chemotherapy in locally advanced breast cancer. JCO. 2016;34(15_suppl):579\u2013579. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.579.","journal-title":"JCO"},{"key":"4485_CR19","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-857423\/v1","author":"S El-Khayat","year":"2021","unstructured":"El-Khayat S, Abouegylah M, Abdallah D, Geweil A, Elenbaby AM, Zahra O. The effect of metformin when combined with neoadjuvant chemotherapy in breast cancer patients. Med Oncol. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-857423\/v1.","journal-title":"Med Oncol"},{"key":"4485_CR20","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1158\/1557-3265.SABCS24-P3-11-17","volume":"31","author":"M Okoniewski","year":"2025","unstructured":"Okoniewski M, Bivona C, Bohnenkamp C, Diaz F, Dai J, Nye L, et al. Abstract P3\u201311-17: a randomized phase II Trial of Neo-adjuvant Chemotherapy with Metformin or Placebo for HER-2 Positive Operable Breast Cancer (The HERMET Trial). Clin Cancer Res. 2025;31:P3-11. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-P3-11-17.","journal-title":"Clin Cancer Res"},{"issue":"86","key":"4485_CR21","doi-asserted-by":"publisher","first-page":"35687","DOI":"10.18632\/oncotarget.26286","volume":"9","author":"B Martin-Castillo","year":"2018","unstructured":"Martin-Castillo B, Pernas S, Dorca J, \u00c1lvarez I, Mart\u00ednez S, P\u00e9rez-Garc\u00eda JM, et al. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget. 2018;9(86):35687\u2013704. https:\/\/doi.org\/10.18632\/oncotarget.26286.","journal-title":"Oncotarget"},{"key":"4485_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz241.003","volume":"30","author":"TY Semiglazova","year":"2019","unstructured":"Semiglazova TY, Osipov M, Krivorotko P, Semiglazov V, Protsenko S, Berstein L, et al. Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer. Ann Oncol. 2019;30:v100. https:\/\/doi.org\/10.1093\/annonc\/mdz241.003.","journal-title":"Ann Oncol"},{"key":"4485_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz241.002","author":"T Semiglazova","year":"2019","unstructured":"Semiglazova T, Osipov M, Krivorotko P, Protsenko S, Semiglazov V, Donskih R, et al. Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz241.002.","journal-title":"Ann Oncol"},{"key":"4485_CR24","doi-asserted-by":"publisher","first-page":"107327482513947","DOI":"10.1177\/10732748251394762","volume":"32","author":"F Xie","year":"2025","unstructured":"Xie F, Jiang T, Qian M, Yu X, Ji J, Song E. Enhancing the efficacy of metformin in neoadjuvant therapy for breast cancer: a meta-analysis based on randomized clinical trials. Cancer Control. 2025;32:10732748251394762. https:\/\/doi.org\/10.1177\/10732748251394762.","journal-title":"Cancer Control"},{"issue":"3","key":"4485_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5603\/DK.2020.0062","volume":"10","author":"HA Al-Ghalib","year":"2021","unstructured":"Al-Ghalib HA, Al-Otaibi AD, Tulaihi BA, Al-Ghaleb S. The anti-proliferative role of metformin in non-diabetic female patients with breast cancer: systematic review and meta-analysis of randomized control trials. Clin Diabetol. 2021;10(3):252\u201360. https:\/\/doi.org\/10.5603\/DK.2020.0062.","journal-title":"Clin Diabetol"},{"key":"4485_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman T, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4485_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers R, Blencowe N, Boutron I, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"4485_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"4485_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-82","volume":"3","author":"N Meader","year":"2014","unstructured":"Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82. https:\/\/doi.org\/10.1186\/2046-4053-3-82.","journal-title":"Syst Rev"},{"issue":"7","key":"4485_CR30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J. 2022;12(7):1624\u20136. https:\/\/doi.org\/10.1177\/21925682221110527.","journal-title":"Global Spine J"},{"key":"4485_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. wiley; 2009. https:\/\/doi.org\/10.1002\/9780470743386."},{"issue":"11","key":"4485_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"4485_CR33","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1016\/j.annonc.2020.08.326","volume":"31","author":"HA Azazy","year":"2020","unstructured":"Azazy HA, Gado NM, Salem DA, El-Ghamry WR. 204P Metformin with neoadjuvant chemotherapy in stage II-III breast cancer: a phase II clinical trial. Ann Oncol. 2020;31:S323\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.326.","journal-title":"Ann Oncol"},{"issue":"6","key":"4485_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31487\/j.COR.2021.06.03","volume":"2021","author":"N Ghimire","year":"2021","unstructured":"Ghimire N, Dharanipragada K, Ghimire N, Dasarathan S, Zachariah B, Toi PC, et al. Efficacy of combining metformin with neoadjuvant chemotherapy on pathologic response in non-diabetic patients with carcinoma breast- a randomized controlled trial. Clin Oncol Res. 2021;2021(6):1\u20137. https:\/\/doi.org\/10.31487\/j.COR.2021.06.03.","journal-title":"Clin Oncol Res"},{"issue":"15_suppl","key":"4485_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.2019.37.15_suppl.576","volume":"37","author":"J Kim","year":"2019","unstructured":"Kim J, Han W, Kim EK, Jung Y, Kim H, Chae SM, et al. Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR study]. JCO. 2019;37(15_suppl):576\u2013576. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.576.","journal-title":"JCO"},{"issue":"24","key":"4485_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70205","volume":"131","author":"BM Mouna","year":"2025","unstructured":"Mouna BM, Batra A, Sharma V, Kataria B, Gogia A, Sharma J, et al. Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: a prospective phase 2 open-label randomized controlled trial (McBETH). Cancer. 2025;131(24):e70205. https:\/\/doi.org\/10.1002\/cncr.70205.","journal-title":"Cancer"},{"issue":"8","key":"4485_CR37","doi-asserted-by":"publisher","first-page":"7453","DOI":"10.48047\/ecb\/2023.12.Si8.639","volume":"12","author":"EH Othman","year":"2024","unstructured":"Othman EH, Fatehy H, Ali K, Nasef K, Hussein O, Elkodary T. Neoadjuvant chemotherapy with or without metformin in invasive non-metastatic breast cancer. Randomized Controll Trial Eur Chem Bull. 2024;12(8):7453\u2013550. https:\/\/doi.org\/10.48047\/ecb\/2023.12.Si8.639.","journal-title":"Randomized Controll Trial Eur Chem Bull"},{"issue":"8","key":"4485_CR38","doi-asserted-by":"publisher","first-page":"10860","DOI":"10.1096\/fj.202000951RR","volume":"34","author":"S Shao","year":"2020","unstructured":"Shao S, Zhao L, An G, Zhang L, Jing X, Luo M, et al. Metformin suppresses HIF-1\u03b1 expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer. FASEB J. 2020;34(8):10860\u201370. https:\/\/doi.org\/10.1096\/fj.202000951RR.","journal-title":"FASEB J"},{"issue":"1","key":"4485_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13058-025-02194-4","volume":"28","author":"R Alim","year":"2025","unstructured":"Alim R, Akalanka HMK. Metformin and its derivatives in breast cancer: from glycaemic control to tumor-intrinsic pathways. Breast Cancer Res. 2025;28(1):13. https:\/\/doi.org\/10.1186\/s13058-025-02194-4.","journal-title":"Breast Cancer Res"},{"key":"4485_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117930","volume":"249","author":"PM Morla-Barcelo","year":"2026","unstructured":"Morla-Barcelo PM, Melguizo-Salom L, Martinez-Bernabe T, Roca P, Sastre-Serra J, Nadal-Serrano M. Metformin reduces senescence induced by obesity-related inflammation in luminal breast cancer through estrogen receptor beta modulation. Biochem Pharmacol. 2026;249:117930. https:\/\/doi.org\/10.1016\/j.bcp.2026.117930.","journal-title":"Biochem Pharmacol"},{"key":"4485_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2021.05.022","volume":"517","author":"HAM Alsheikh","year":"2021","unstructured":"Alsheikh HAM, Metge BJ, Ha CM, Hinshaw D, Mota MSV, Kammerud SC, et al. Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. Cancer Lett. 2021;517:24\u201334. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.022.","journal-title":"Cancer Lett"},{"issue":"11","key":"4485_CR42","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1634\/theoncologist.2015-0096","volume":"20","author":"H Xu","year":"2015","unstructured":"Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncol. 2015;20(11):1236\u201344. https:\/\/doi.org\/10.1634\/theoncologist.2015-0096.","journal-title":"Oncol"},{"issue":"3","key":"4485_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/jcpt.13500","volume":"47","author":"Q Wang","year":"2022","unstructured":"Wang Q, Ma X, Long J, Du X, Pan B, Mao H. Metformin and survival of women with breast cancer: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(3):263\u20139. https:\/\/doi.org\/10.1111\/jcpt.13500.","journal-title":"J Clin Pharm Ther"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04485-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04485-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:14:47Z","timestamp":1783091687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04485-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":43,"alternative-id":["4485"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04485-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval and consent to participate were not required for the current review and meta-analysis, as it exclusively utilized data from previously published studies. No human subjects were directly involved, and all data sources were publicly available or anonymized in accordance with ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}